“The evidence shows that Zio XT increases how many people are diagnosed with cardiac arrhythmias. Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, said: “This easy to use and innovative technology can aid the detection of cardiac arrhythmias with continuous monitoring for up to 14 days while allowing the patient to get on with their everyday life. The process can be contact free, especially useful during the COVID-19 pandemic, allowing the patient to first have a telephone/video consultation before the Zio XT biosensor is dispatched direct to their home.Ĭurrently 12 hospital trusts across England are evaluating the Zio XT service, which costs £265 per patient. A full report is then supplied to the NHS clinician for final analysis and interpretation. The ECG recordings are analysed using an artificial intelligence developed algorithm, overseen by the company’s cardiographic technicians. After use the patient removes the patch and sends it via freepost for analysis. It is worn constantly for up to 14 days and can be fitted by a patient at home, discreetly underneath their clothes.Īs the patch can be worn for up to two weeks, the amount of analysable data is larger than the 24-hour Holter monitor which is current NHS standard practice and therefore Zio XT is more likely to pick up arrhythmia. ![]() The biosensor patch is a small, lightweight, easy to wear electrocardiogram (ECG), that records and measures the heart's electrical activity. The Zio XT service comprises a waterproof biosensor patch and a report with a summary of data that has been analysed using an artificial intelligence (AI) led algorithm. Zio XT service could – if commissioned by the NHS – be used by more than 150,000 people. Another 500,000 people are believed to be living with undiagnosed AF. More than 1.2 million people in the UK are diagnosed with having atrial fibrillation (AF), one of the most common cardiac arrhythmias, an abnormality of the heart's rhythm. After this time, NICE’s committee will review the technology with the new evidence and make a final recommendation on whether to recommend Zio XT for routine use on the NHS. Patients will have access to this promising new technology for three years while more data is collected to address evidence gaps about its benefit. ![]() NICE has today published medical technology guidance which recommends the Zio XT service for detecting abnormal heart rhythms, only if NHS organisations collect further evidence of its benefits.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |